CRMD Stock Summary and Trading Ideas (Cormedix | NASDAQ:CRMD)

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Cormedix trades on the NASDAQ stock market under the symbol CRMD.

As of February 11, 2025, CRMD stock price declined to $10.05 with 542,986 million shares trading.

CRMD has a beta of 1.93, meaning it tends to be more sensitive to market movements. CRMD has a correlation of 0.10 to the broad based SPY ETF.

CRMD has a market cap of $609.81 million. This is considered a Small Cap stock.

Last quarter Cormedix reported $11 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $616,000 and exceeded earnings estimates by $.05.

In the last 3 years, CRMD traded as high as $13.85 and as low as $2.57.

The top ETF exchange traded funds that CRMD belongs to (by Net Assets): IWM, VTI, VXF, IWO, IBB.

CRMD has outperformed the market in the last year with a return of +216.0%, while the SPY ETF gained +22.2%. However, in the most recent history, CRMD shares have underperformed the stock market with its stock returning -13.4% in the last 3 month period and -18.8% for the last 2 week period, while SPY has returned +1.5% and +1.0%, respectively.

CRMD support price is $9.86 and resistance is $10.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.